In: Virus Evolution, 2017, vol. 3, no. 1, p. -
|
In: Cancers, 2020, vol. 12, no. 3, p. 532
Poly(ADP-ribose) polymerase (PARP) inhibitors have recently been introduced in the therapy of several types of cancers not responding to conventional treatments. However, de novo and acquired PARP inhibitor resistance is a significant limiting factor in the clinical therapy, and the underlying mechanisms are not fully understood. Activity of the cytoprotective phosphatidylinositol-3 kinase...
|
In: iScience, 2019, vol. 19, p. 39–53
Insulin-induced AKT activation is dependent on phosphoinositide 3-kinase and opposed by tumor suppressor phosphatase and tensin homolog (PTEN). Our previous study demonstrates that myosin 1b (MYO1B) mediates arginase-II-induced activation of mechanistic target of rapamycin complex 1 that is regulated by AKT. However, the role of MYO1B in AKT activation is unknown. Here we show that silencing...
|
In: Biochemical Pharmacology, 2019, vol. 162, p. 98–108
The cytoprotective effect of poly(ADP-ribose) polymerase 1 (PARP1) inhibition is well documented in various cell types subjected to oxidative stress. Previously, we have demonstrated that PARP1 inhibition activates Akt, and showed that this response plays a critical role in the maintenance of mitochondrial integrity and in cell survival. However, it has not yet been defined how nuclear PARP1...
|
In: Journal of Mammary Gland Biology and Neoplasia, 2006, vol. 11, no. 1, p. 53-61
|
In: Journal of Genetics, 2010, vol. 89, no. 3, p. 315-323
|
In: Neurosurgical Review, 2003, vol. 26, no. 3, p. 145-158
|
In: Journal Of The National Cancer Institute, 2015, vol. 107, no. 7, p. -
|
In: European Journal of Cardio-Thoracic Surgery, 2008, vol. 33, no. 3, p. 501-505
|
In: The Journal of Biochemistry, 1999, vol. 126, no. 6, p. 1136-1143
|